A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2013
At a glance
- Drugs Taladegib (Primary)
- Indications Medulloblastoma; Rhabdomyosarcoma
- Focus Adverse reactions
- 26 Aug 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 May 2013 Planned initiation date changed from 1 Apr 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 29 Mar 2013 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.